An update on the diagnosis and treatment of leprosy

Journal of the American Academy of Dermatology

Volumn 51, Issue 3, 2004, Pages 417-426

  Moschella, Samuel L ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; CORTICOSTEROID; DAPSONE; LEPROSY VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RIFAMPICIN; THALIDOMIDE;

BORDERLINE LEPROSY; COSTA RICA; DISEASE CLASSIFICATION; DISEASE CONTROL; DRUG EFFICACY; ENDEMIC DISEASE; ERYTHEMA NODOSUM LEPROSUM; ETHIOPIA; FACIAL NERVE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; LEPROMATOUS LEPROSY; LEPROMIN TEST; LEPROSY; MEDIAN NERVE; MEXICO; MYCOBACTERIUM LEPRAE; PATHOGENICITY; PERONEUS NERVE; POSTERIOR TIBIAL NERVE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; SMEAR; SOCIOECONOMICS; TUBERCULOID LEPROSY; ULNAR NERVE; WORLD HEALTH ORGANIZATION;

BACTERIAL VACCINES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ACTIVE; INCIDENCE; LEPROMIN; LEPROSTATIC AGENTS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL EXAMINATION; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE; SENSITIVITY AND SPECIFICITY; VACCINATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 4444319180     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.11.072     Document Type: Review

References (37)

1. Report of the International Leprosy Association Technical Forum. The global situation of leprosy control of the 21st century. Int J Lepr Other Mycobact Dis. 70:2002;521-522
2. Visschedijk J., van de Broek J., Eggens H., Lever P., van Beers S., Klatser P. Mycobacterium leprae - millennium resistant! Leprosy control on the threshold of a new era. Trop Med Int Health. 5:2000;388-399
3. Pfeifer LA. A summary of Hansen's disease in the United States - 2001. Presented at the Seminar on Hansen's Disease, National Hansen's Disease Program; February 26, 2003.
4. Naafs B. Viewpoint: leprosy after the year 2000. Trop Med Int Health. 5:2000;400-403
5. Bryceson A., Pfaltzgraff R.E. Diagnosis. Bryceson A., Pfaltzgraff R.E. Leprosy. 1990;57-75 Churchill Livingstone, Edinburgh
6. Report of the International Leprosy Association Technical Forum. Diagnosis and classification of leprosy. Int J Lepr Other Mycobact Dis. 70:2002;523-531
7. WHO Expert Committee on Leprosy. 7th Report (WHO Technical Report Series, No.874). 1998;World Health Organization, Geneva
8. Weng X.M., Chen S.Y., Ran S.P., Zhang C.H., Li H.Y. Immuno-histopathology in the diagnosis of early leprosy. Int J Lepr Other Mycobact Dis. 68:2000;426-433
9. Buhrer-Sekula S., Sarno E.N., Oskam L., Koop S., Wichers I., Nery J.A., et al. Use of ML dipstick as a tool to classify leprosy patients. Int J Lepr Other Mycobact Dis. 68:2000;456-463
10. Scollard D.M., Gillis T.P., Williams D.L. Polymerase chain reaction assay for the detection and identification of Mycobacterium leprae in patients in the United States. Am J Clin Pathol. 109:1998;642-646
11. Dharmendra. Classification of leprosy. Hastings R.C. Leprosy. 1985;88-99 Churchill Livingstone, Edinburgh
12. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 34:1966;255-273
13. World Health Organization. Leprosy Elimination Advisory Group. Guide to eliminate leprosy as a public health problem: multidrug therapy cures leprosy, stops transmission and prevents disabilities. 2000;Leprosy Elimination Group, World Health Organization, Geneva
14. Rose P., Waters M.F. Reversal reactions in leprosy and their management. Lepr Rev. 62:1991;113-121
15. Guerra J.G., Penna G.O., de Castro L.C., Martelli C.M., Stefani M.M. Erythema nodosum leprosum: clinical and therapeutic up-date. An Bras Dermatol. 77:2002;389-407
16. Becx-Bleumink M., Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 60:1992;173-184
17. Moschella S.L. The lepra reaction with necrotizing skin lesions. A report of six cases. Arch Dermatol. 95:1967;565-575
18. Ortiz Y., Finer M. Lucio's leprosy (diffuse lepromatous leprosy) II. Recent advances, clinical and laboratory data. Dermatol Rev Mex. 22:1978;141-163
19. Rea T.H. Lucio's phenomenon: an overview. Lepr Rev. 50:1979;107-112
20. Duncan M.E., Melsom R., Pearson J.M., Ridley D.S. The association of pregnancy and leprosy I. New cases, relapse of cured patients and deterioration in patients on treatment during pregnancy and lactation - results of a prospective study of 154 pregnancies in 147 Ethiopian women. Lepr Rev. 52:1981;245-262
21. Lockwood D.N., Sinha H.H. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis. 67:1999;6-12
22. Gebre S., Saunderson P., Messele T., Byass P. The effect of HIV status on the clinical picture of leprosy: a prospective study in Ethiopia. Lepr Rev. 71:2000;338-343
23. Lucas S. Human immunodeficiency virus and leprosy. Lepr Rev. 64:1993;97-103
24. WHO Study Group on Chemotherapy of Leprosy for Control Programmes. Chemotherapy of leprosy for control programmes: report of a WHO study group. 1982;World Health Organization, Geneva
25. Ji B. Prospects for chemotherapy of leprosy. Indian J Lepr. 72:2000;187-198
26. Bhattacharya S.N., Sehgal V.N. Reappraisal of the drifting scenario of leprosy multi-drug therapy: new approach proposed for the new millennium. Int J Dermatol. 41:2002;321-326
27. van Brakel W.H., Khawas I.B. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev. 65:1994;350-360
28. Talwar G.P. An immunotherapeutic vaccine for multibacillary leprosy. Int Rev Immunol. 18:1999;229-249
29. Azulay D.R. Antileprosy vaccinations. An Bras Dermatol. 77:2002;489-494
30. Zaheer S.A., Misra R.S., Sharma A.K., Beena K.R., Kar H.K., Mukherjee A., et al. Immunotherapy with Mycobacterium w vaccine decreases the incidence and severity of type 2 (ENL) reactions. Lepr Rev. 64:1993;7-14
31. Lockwood D.N. The management of erythema nodosum leprosum: current and future options. Lepr Rev. 67:1996;253-259
32. Stanley J.N., Kirnan K.U., Pearson J.M. The use of colchicine in the management of type II reaction (erythema nodosum leprosum). Lepr Rev. 55:1984;317-318
33. Nery J.A., Perisse A.R., Sales A.M., Vieira L.M., Souza R.V., Sampaio E.P., et al. The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J Lepr. 72:2000;457-467
34. Miller R.A., Shen J.Y., Rea T.H., Harnisch J.P. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Int J Lepr Other Mycobact Dis. 55:1987;441-449
35. Escalona E. La lepra en la actualidad. Medico. 4:1954;26-28
36. Leprosy disabilities: magnitude of the problem. Wkly Epidemiol Rec. 70:1995;269-275
37. Ladhani S. Leprosy disabilities: the impact of multidrug therapy (MDT). Int J Dermatol. 36:1997;561-572